Author:
Handley Nathan R.,Feng Felix Y.,Guise Theresa A.,D'Andrea Denise,Kelly William Kevin,Gomella Leonard G.
Funder
Clovis Oncology
Merck
Bayer Fund
Janssen Biotech
Janssen Scientific Affairs
Astellas Pharma US
AstraZeneca
AbbVie
Reference85 articles.
1. Lowrance WT, Breau R, Chou R, et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline. Available at: http://www.auanet.org/guidelines/advanced-prostate-cancer. Accessed September 18, 2020.
2. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020
3. The molecular evolution of castration-resistant prostate cancer;Ceder;Eur Urol Focus,2016
4. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial;Fizazi;Lancet Oncol,2019
5. Apalutamide for metastatic, castration-sensitive prostate cancer;Chi;N Engl J Med,2019